China Cord May Hurt Minority Share Holders

Summary

CSRC passed the inquiry regarding low bid price for China Cord's minority share holders.

HKEX lacks track-records to interfere similar issues.

Watch out for SEC interventions for the last straw.

This is article is published on Seeking Alpha now. Please go to
http://seekingalpha.com/article/3972227-china-cord-may-hurt-minority-share-holders

Thanks

 

Valuation Analysis On Clinical-Stage Biotech

Executive Summary

Aduro Biotech Inc. (NASDAQ:ADRO) is a clinical-stage immunotherapy company and focuses on the discovery, development, and commercialization of treatments for challenging diseases. We analyzed the firm on the assumption of it producing only a single drug, CRS-207, and only applying to pancreatic treatment. We concluded a risk-adjusted price target of $6.70 for this business line.

This is article is published on Seeking Alpha now. Please go to http://seekingalpha.com/article/3971097-valuation-analysis-clinical-stage-biotech

Thanks